NasdaqGM:KODBiotechs
Kodiak Sciences (KOD): Assessing Valuation After Its $160 Million Capital Raise for Late-Stage Pipeline
Kodiak Sciences (KOD) just wrapped up a sizable follow on stock offering, raising roughly $160 million to help fund its late stage eye disease drug programs and shore up its balance sheet.
See our latest analysis for Kodiak Sciences.
That capital raise lands after a huge run, with Kodiak’s 90 day share price return of 73.22 percent and year to date share price return of 201.62 percent, signalling strong, speculative momentum despite a bruising 5 year total shareholder return of negative 83.12...